CellUranics has recently completed its Series A1 funding round, raising hundreds of millions of RMB. The round was co-led by Puhua Capital, Acorn Capital, Jinshuihu Fund, and Green Fund, with proceeds primarily allocated to the construction of a 10,000-tonne-scale 2,5-furandicarboxylic acid (FDCA) flagship plant in Jiande, Zhejiang Province. This facility — the world’s first FDCA plant based on the glucaric acid (GA) intermediate route — is set to advance from technical validation to scaled commercial production.
To date, the company has brought together a distinguished group of financial and strategic investors, including Sequoia Capital China Seed Fund, Puhua Capital, Blueprint Ventures, Acorn Capital, Jinshuihu Fund, Green Fund, and Westlake Photon, building a shareholder base that combines strong capital backing with industrial empowerment capabilities.
As one of the most closely watched platform compounds in the bio-based materials sector, FDCA’s industrialization is widely regarded as a key barometer of whether bio-manufacturing can break out of niche applications and enter the commodity materials market. This funding milestone provides critical support for China’s FDCA industry to advance toward 10,000-tonne-scale production validation. As the plant comes online, it is expected to offer a viable and practical technology pathway for the green transformation of the traditional chemical industry.